Mizuho's Holz on weight loss drugs: Lilly and Novo Nordisk are in excellent shape fundamentally

Mizuho's Holz on weight loss drugs: Lilly and Novo Nordisk are in excellent shape fundamentallyПодробнее

Eli Lilly and Novo Nordisk will remain leaders in the weight-loss drug market: Mizuho's Jared HolzПодробнее

New developments in weight-loss drugs: Novo Nordisk, Eli Lilly & Pfizer advance studiesПодробнее

Zealand's obesity drug shouldn't disrupt Novo Nordisk-Eli Lilly leadership: Mizuho's Jared HolzПодробнее

Former FDA commissioner: Expect more competition in Eli Lilly and Novo Nordisk's weight-loss drugsПодробнее

Mizuho's Jared Holz on Novo Nordisk: There's not much upside near-termПодробнее

How Ozempic And Wegovy Accidentally Made Novo Nordisk A $400B CompanyПодробнее

Obesity drug supply-demand imbalance is working in Novo Nordisk's favor: Mizuho's Jared HolzПодробнее

Barclays: Novo Nordisk and Eli Lilly have first-move advantage in the obesity drug raceПодробнее

People are 'scratching and clawing' for negative narrative around obesity drugs: Mizuho's Jared HolzПодробнее

Jim Cramer weighs the market impact of Eli Lilly and Novo Nordisk's weight loss drugsПодробнее

Novo Nordisk shares pop after key trial data shows Wegovy cuts risk of heart attack or stroke by 20%Подробнее

Obesity weight loss market will remain a duopoly between Novo Nordisk and Eli Lilly: BofA’S MeachamПодробнее

Eli Lilly, Novo Nordisk to test weight loss drugs for childrenПодробнее

Weight loss drug market is just beginning to take off, says Mizuho's Jared HolzПодробнее

Weight loss drugs are 'huge market' for pharmaceuticals: AnalystПодробнее

Eli Lilly's DTC obesity drug push 'not necessarily an industry game changer': Mizuho's Jared HolzПодробнее

Obesity drug maker Novo Nordisk lifts outlook again | REUTERSПодробнее

TIME100 Most Influential Companies: Novo NordiskПодробнее

Obesity drug enthusiasm can continue in 2024: Mizuho's Jared HolzПодробнее